Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Diagnosis, management and treatment of the Alport syndrome : 2024 guideline on behalf of ERKNet, ERA and ESPN
Avtorji:ID Torra, Roser (Avtor)
ID Lipska-Zietkiewicz, Beata (Avtor)
ID Acke, Frederic (Avtor)
ID Antignac, Corinne (Avtor)
ID Becker, Jan Ulrich (Avtor)
ID Cornec-Le Gall, Emilie (Avtor)
ID Eerde, Albertien M van (Avtor)
ID Feltgen, Nicolas (Avtor)
ID Kopač, Matjaž (Avtor), et al.
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (921,15 KB)
MD5: 8F729D4193708A8D31FDF33EC232800B
 
URL URL - Izvorni URL, za dostop obiščite https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfae265/60935294/gfae265.pdf
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with sensorineural deafness, and occasionally with ocular anomalies. Diagnosis and management of COL4A3/4/5 glomerulopathy is a great challenge due to its phenotypic heterogeneity, multiple modes of inheritance, variable expressivity, and disease penetrance of individual variants as well as imperfect prognostic and progression factors and scarce and limited clinical trials, especially in children. As a joint initiative of the European Rare Kidney disease reference Network (ERKNet), European Renal Association (ERA Genes&Kidney), and European Society for Paediatric Nephrology (ESPN) Inherited renal disorders working group, a team of experts including adult and paediatric nephrologists, kidney geneticists, audiologists, ophthalmologists, and a kidney pathologist were selected to perform a systematic literature review on 21 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions. The experts formulated recommendations and formally graded them at a consensus meeting with input from patient representatives and a voting panel of nephrologists representing all regions of the world. Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation of an individual presenting with persistent haematuria, proteinuria, kidney failure of unknown origin, focal segmental sclerosis of unknown origin, and possibly cystic kidney disease. Early renin-angiotensin system blockade is the standard of care therapy; sodium-glucose cotransporter-2 inhibitors may be added in adults with proteinuria and chronic kidney disease. Relatives with heterozygous COL4A3/4/5 variants should only be considered as the last possible resource for living kidney donation. This guideline provides guidance for the diagnosis and management of individuals with pathogenic variants in COL4A3/4/5 genes.
Ključne besede:Alport syndrome, glomerular basement membrane, haematuria
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1091–1106
Številčenje:Vol. 40, iss. 6
PID:20.500.12556/DiRROS-27910 Novo okno
UDK:616.6
ISSN pri članku:1460-2385
DOI:10.1093/ndt/gfae265 Novo okno
COBISS.SI-ID:235767555 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 13. 5. 2025;
Datum objave v DiRROS:27.02.2026
Število ogledov:159
Število prenosov:48
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Nephrology dialysis transplantation
Skrajšan naslov:Nephrol. dial. transplant.
Založnik:Oxford University Press
ISSN:1460-2385
COBISS.SI-ID:3510449 Novo okno

Gradivo je financirano iz projekta

Financer:EC - European Commission
Številka projekta:101085068
Naslov:Support Coordinating Centres of the 24 ERNs for the Coordination, Management, and Operational Activities of the ERNs

Financer:Drugi - Drug financer ali več financerjev
Program financ.:German Federal Ministry of Education and Research
Številka projekta:01KG1104
Naslov:EARLY PRO-TECT Alport

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Deutsche Forschungsgemeinschaft
Številka projekta:508779211
Naslov:DOUBLE PRO-TECT Alport

Financer:Drugi - Drug financer ali več financerjev

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj